/
/
/

Fredun Pharmaceuticals Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
---40%
---65%
-64%65%257%
15%15%15%16%

Peer Comparison

Symbol
SUNPHARMA-A
DIVISLAB-A
TORNTPHARM-A
ZYDUSLIFE-A
CIPLA-A
LAURUSLABS-A
LUPIN-A
MANKIND-A
DRREDDY-A
AUROPHARMA-A
FREDUN-B
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,904₹463791 Cr38.3412.0762.82₹11479 Cr
9,245₹245081 Cr83.7934.04128.41₹2568 Cr
4,924.7₹190351 Cr87.2816.7297.06₹2163 Cr
1,135₹114833 Cr25.449.4262.53₹5040 Cr
1,389₹114163 Cr33.879.7757.87₹3879 Cr
1,872.15₹100660 Cr92.066.829.25₹889 Cr
2,135₹98431 Cr17.830.95154.36₹5333 Cr
2,345₹98305 Cr48.1313.7571.08₹1913 Cr
1,155₹96906 Cr30.075.3263.99₹4196 Cr
1,627₹95300 Cr25.6717.9596.84₹3505 Cr
1,500₹2491 Cr56.847.9432.79₹33 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
₹228 Cr₹213 Cr₹161 Cr₹145 Cr₹120 Cr₹167 Cr
₹228 Cr₹213 Cr₹161 Cr₹145 Cr₹120 Cr₹167 Cr
₹199 Cr₹187 Cr₹136 Cr₹125 Cr₹104 Cr₹152 Cr
₹33 Cr₹29 Cr₹26 Cr₹22 Cr₹17 Cr₹17 Cr
₹9 Cr₹14 Cr₹11 Cr₹8 Cr₹7 Cr₹8 Cr
₹21 Cr₹11 Cr₹14 Cr₹13 Cr₹9 Cr₹7 Cr
₹13 Cr₹11 Cr₹10 Cr₹9 Cr₹7 Cr₹6 Cr

Balance Sheet

Consolidated
Standalone
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025
₹5 Cr₹5 Cr
₹14 Cr₹0
₹259 Cr₹137 Cr
₹259 Cr₹137 Cr
₹278 Cr₹141 Cr
-₹1,000₹0
₹56 Cr₹10 Cr
₹7 Cr₹4 Cr
₹0₹2,000
₹4 Cr₹4 Cr
₹67 Cr₹18 Cr
₹88 Cr₹145 Cr
₹53 Cr₹26 Cr
₹146 Cr₹151 Cr
₹10 Cr₹7 Cr
₹297 Cr₹328 Cr
₹642 Cr₹487 Cr
₹222 Cr₹167 Cr
₹148 Cr₹75 Cr
₹30 Cr₹22 Cr
₹118 Cr₹53 Cr
₹2 Cr₹2 Cr
₹2 Cr₹2 Cr
₹12 Cr₹5 Cr
₹11 Cr₹76 L
₹144 Cr₹60 Cr
₹270 Cr₹240 Cr
₹93 Cr₹177 Cr
₹65 Cr₹5 Cr
₹7 Cr₹3 Cr
₹64 Cr₹2 Cr
₹498 Cr₹427 Cr
₹201 Cr₹99 Cr
₹642 Cr₹487 Cr
₹483₹299
₹483₹299

Cash Flow

Consolidated
Standalone
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025
₹35 Cr₹27 Cr
₹46 Cr₹28 Cr
-₹69 Cr-₹72 Cr
₹12 Cr-₹17 Cr
₹12 Cr-₹17 Cr
-₹74 Cr-₹6 Cr
₹121 Cr₹27 Cr
₹60 Cr₹4 Cr
₹5 Cr₹2 Cr
₹65 Cr₹5 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)1,525.00
Volume (₹)3,742.00
High (₹)1,525.00
Upper Circuit1,656.75
Low (₹)1,484.00
Lower Circuit1,355.55
Prev Close1,506.15
52W High (₹)1,600.00
Price1,500.00
52W Low (₹)390.57

Share Market Cap & Key Ratios Overview

M.Cap (₹)2490.88 Cr
Div. Yield (%)0.02
PE Ratio56.84
Debt to Equity0.84
Price to Book3.46
Book Value160.92
EPS (TTM)26.50
Face Value10.00
ROE (%)16.09

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMA-ANSE
DIVISLAB-ANSE
TORNTPHARM-ANSE
ZYDUSLIFE-ANSE
CIPLA-ANSE
LAURUSLABS-ANSE
LUPIN-ANSE
MANKIND-ANSE
DRREDDY-ANSE
AUROPHARMA-ANSE
FREDUN-BNSE
LTP
1W Low
1W High
Market cap (₹)
1904-16.1 (-0.84%)
1901
1964.85
4,63,791Cr
9245-24 (-0.26%)
9051.85
9296
2,45,081Cr
4924.7-110.3 (-2.19%)
4890
5049
1,90,351Cr
1135-52 (-4.38%)
1130.75
1191.45
1,14,833Cr
1389-29 (-2.05%)
1388.50
1426.20
1,14,163Cr
1872.15-63.15 (-3.26%)
1812
1947.90
1,00,660Cr
2135-40 (-1.84%)
2135
2209
98,431Cr
2345-42.4 (-1.78%)
2323.15
2407.40
98,305Cr
1155-22.8 (-1.94%)
1155
1179.90
96,906Cr
1627-23 (-1.39%)
1627
1706.70
95,300Cr
1500+22.95 (1.55%)
1433
1529
2,491Cr

Fredun Pharmaceuticals Ltd Annual Results Key Takeaways

Interest expense was ₹8.62Cr; PBT before exceptional items stood at ₹20.55Cr. Cost mix (full year): raw materials ₹485.84Cr; employee cost ₹32.94Cr; depreciation ₹3.57Cr; other expenses ₹195.51Cr. Basis: consolidated annual results.

Fredun Pharmaceuticals Ltd Quaterly Results Key Takeaways

Fredun Pharmaceuticals Ltd reported ₹228.25Cr total income from operations in Jun 2026, softer than ₹213.06Cr in Mar 2026 but higher than ₹119.86Cr in Jun 2025. Interest expense was ₹8.62Cr, taking profit before tax to ₹20.55Cr. After tax of ₹7.42Cr, profit after tax stood at ₹13.13Cr (vs ₹10.78Cr in Mar 2026 and ₹6.76Cr in Jun 2025).